Examining Associations Between Smartphone Use and Clinical Severity in Frontotemporal Dementia: Proof-of-Concept Study.

Autor:	Paolillo EW; Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States., Casaletto KB; Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States., Clark AL; Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States., Taylor JC; Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States., Heuer HW; Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States., Wise AB; Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States., Dhanam S; Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States., Sanderson-Cimino M; Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States., Saloner R; Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States., Kramer JH; Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States., Kornak J; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, United States., Kremers W; Department of Quantitative Health Sciences, Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, United States., Forsberg L; Department of Neurology, Mayo Clinic, Rochester, MN, United States., Appleby B; Department of Neurology, Case Western Reserve University, Cleveland, OH, United States., Bayram E; Department of Neurosciences, University of California, San Diego, La Jolla, CA, United States., Bozoki A; Department of Neurology, University of North Carolina, Chapel Hill, NC, United States., Brushaber D; Department of Quantitative Health Sciences, Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, United States., Darby RR; Department of Neurology, Vanderbilt University, Nashville, TN, United States., Day GS; Department of Neurology, Mayo Clinic, Jacksonville, FL, United States., Dickerson BC; Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States., Domoto-Reilly K; Department of Neurology, University of Washington, Seattle, WA, United States., Elahi F; Department of Neurology, The Deane Center for Wellness and Cognitive Health, Icahn School of Medicine at Mount Sinai, New York, NY, United States.; James J. Peters Veterans Affairs Medical Center, New York, NY, United States., Fields JA; Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, United States., Ghoshal N; Department of Neurology, Knight Alzheimer's Disease Research Center, Washington University, St. Louis, MO, United States., Graff-Radford N; Department of Neurology, Mayo Clinic, Jacksonville, FL, United States., G H Hall M; Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States., Honig LS; Department of Neurology, Columbia University, New York, NY, United States., Huey ED; Department of Psychiatry and Human Behavior, Brown University, Providence, RI, United States., Lapid MI; Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, United States., Litvan I; Department of Neurosciences, University of California, San Diego, La Jolla, CA, United States., Mackenzie IR; Department of Pathology, University of British Columbia, Vancouver, BC, Canada., Masdeu JC; Stanley H. Appel Department of Neurology, Nantz National Alzheimer Center, Houston Methodist Research Institute, Weill Cornell Medicine, Houston, TX, United States., Mendez MF; Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States., Mester C; Department of Quantitative Health Sciences, Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, United States., Miyagawa T; Department of Neurology, Mayo Clinic, Rochester, MN, United States., Naasan G; Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, United States., Pascual B; Stanley H. Appel Department of Neurology, Nantz National Alzheimer Center, Houston Methodist Research Institute, Weill Cornell Medicine, Houston, TX, United States., Pressman P; Department of Neurology, University of Colorado, Aurora, CO, United States., Ramos EM; Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States., Rankin KP; Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States., Rexach J; Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States., Rojas JC; Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States., VandeVrede L; Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States., Wong B; Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States., Wszolek ZK; Department of Neurology, Mayo Clinic, Jacksonville, FL, United States., Boeve BF; Department of Neurology, Mayo Clinic, Rochester, MN, United States., Rosen HJ; Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States., Boxer AL; Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States., Staffaroni AM; Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States.
Jazyk:	angličtina
Zdroj:	JMIR aging [JMIR Aging] 2024 Jun 26; Vol. 7, pp. e52831. Date of Electronic Publication: 2024 Jun 26.
DOI:	10.2196/52831
Abstrakt:	Background: Frontotemporal lobar degeneration (FTLD) is a leading cause of dementia in individuals aged <65 years. Several challenges to conducting in-person evaluations in FTLD illustrate an urgent need to develop remote, accessible, and low-burden assessment techniques. Studies of unobtrusive monitoring of at-home computer use in older adults with mild cognitive impairment show that declining function is reflected in reduced computer use; however, associations with smartphone use are unknown. Objective: This study aims to characterize daily trajectories in smartphone battery use, a proxy for smartphone use, and examine relationships with clinical indicators of severity in FTLD. Methods: Participants were 231 adults (mean age 52.5, SD 14.9 years; n=94, 40.7% men; n=223, 96.5% non-Hispanic White) enrolled in the Advancing Research and Treatment of Frontotemporal Lobar Degeneration (ARTFL study) and Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS study) Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) Mobile App study, including 49 (21.2%) with mild neurobehavioral changes and no functional impairment (ie, prodromal FTLD), 43 (18.6%) with neurobehavioral changes and functional impairment (ie, symptomatic FTLD), and 139 (60.2%) clinically normal adults, of whom 55 (39.6%) harbored heterozygous pathogenic or likely pathogenic variants in an autosomal dominant FTLD gene. Participants completed the Clinical Dementia Rating plus National Alzheimer's Coordinating Center Frontotemporal Lobar Degeneration Behavior and Language Domains (CDR+NACC FTLD) scale, a neuropsychological battery; the Neuropsychiatric Inventory; and brain magnetic resonance imaging. The ALLFTD Mobile App was installed on participants' smartphones for remote, passive, and continuous monitoring of smartphone use. Battery percentage was collected every 15 minutes over an average of 28 (SD 4.2; range 14-30) days. To determine whether temporal patterns of battery percentage varied as a function of disease severity, linear mixed effects models examined linear, quadratic, and cubic effects of the time of day and their interactions with each measure of disease severity on battery percentage. Models covaried for age, sex, smartphone type, and estimated smartphone age. Results: The CDR+NACC FTLD global score interacted with time on battery percentage such that participants with prodromal or symptomatic FTLD demonstrated less change in battery percentage throughout the day (a proxy for less smartphone use) than clinically normal participants (P<.001 in both cases). Additional models showed that worse performance in all cognitive domains assessed (ie, executive functioning, memory, language, and visuospatial skills), more neuropsychiatric symptoms, and smaller brain volumes also associated with less battery use throughout the day (P<.001 in all cases). Conclusions: These findings support a proof of concept that passively collected data about smartphone use behaviors associate with clinical impairment in FTLD. This work underscores the need for future studies to develop and validate passive digital markers sensitive to longitudinal clinical decline across neurodegenerative diseases, with potential to enhance real-world monitoring of neurobehavioral change. (©Emily W Paolillo, Kaitlin B Casaletto, Annie L Clark, Jack C Taylor, Hilary W Heuer, Amy B Wise, Sreya Dhanam, Mark Sanderson-Cimino, Rowan Saloner, Joel H Kramer, John Kornak, Walter Kremers, Leah Forsberg, Brian Appleby, Ece Bayram, Andrea Bozoki, Danielle Brushaber, R Ryan Darby, Gregory S Day, Bradford C Dickerson, Kimiko Domoto-Reilly, Fanny Elahi, Julie A Fields, Nupur Ghoshal, Neill Graff-Radford, Matthew G H Hall, Lawrence S Honig, Edward D Huey, Maria I Lapid, Irene Litvan, Ian R Mackenzie, Joseph C Masdeu, Mario F Mendez, Carly Mester, Toji Miyagawa, Georges Naasan, Belen Pascual, Peter Pressman, Eliana Marisa Ramos, Katherine P Rankin, Jessica Rexach, Julio C Rojas, Lawren VandeVrede, Bonnie Wong, Zbigniew K Wszolek, Bradley F Boeve, Howard J Rosen, Adam L Boxer, Adam M Staffaroni, ALLFTD Consortium. Originally published in JMIR Aging (https://aging.jmir.org), 26.06.2024.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu